Trial results

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

NCT07639021 on ClinicalTrials.gov · last registry update 2026-09-16

An unusually large phase 2: 233 participants, more than double the 110 typical for the stage. Due to report 14 June 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Number of gastrointestinal adverse events. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 3 times since then.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

233

Started

2026-06-09

Primary completion

2027-06-14 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Number of gastrointestinal adverse events

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.